CHIEF-PD: Cholinesterase Inhibitor to prEvent Falls in Parkinson’s Disease
Objective: Preventing falls in people with Parkinson’s disease has the potential to reduce hospital admissions and improve quality of life by diminishing the significant morbidity…Rivastigmine for visual hallucinations in Parkinson’s disease
Objective: The aim of the study is to investigate whether early rivastigmine treatment of visual hallucinations in patients with Parkinson's disease delays the progression of…An open labeled, observational study for the Satisfaction and Preference of the Rivastigmine patch for treatment of Alzheimer’s disease and Parkinson’s disease dementia (SAFE-ADPD) in Koreans
Objective: This study performed to access caregiver’s satisfaction and preference of the Rivastigmine patch for treatment of Alzheimer’s disease and Parkinson’s disease dementia patients to…Rivastigmine solution in the one-year treatment of Parkinson’s disease dementia and dementia with Lewy bodies
Objective: Efficacy and safety of rivastigmine solution in the treatment of dementia with Lewy bodies (DLB) and Parkinson’s disease dementia (PDD) is not well studied…Do Acetylcholinesterase Inhibitors (AChEI) delay institutionalisation in Parkinson’s and Lewy Body Disease?
Objective: We explored the use of Rivastigmine in Parkinson’s and Lewy body dementia through assessment of quantitative data obtained from a clinical database. We focussed…Effect of rivastigmine in Parkinson’s disease dementia – A logitudinal observational study
Objective: Outcome of Rivastigmine treatment in Parkinson's disease Dementia (PDD). Effect of treatment on cognition and Neuropsychiatric symptoms. To compare clinical global impression of Clinicians…
Abstracts from the International Congress of Parkinson’s and Movement Disorders.